GSK · story · 25 October – 27 October
GSK · 8 headlines from 7 outlets, from 25 October 2026 to 27 October 2026.
GSK reported Jemperli data showing a 76% complete response rate in rectal cancer, with no recurrences so far among responders.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
TradingView is the largest at 10.0, ahead of Proactive Investors UK (10.0). Sharecast is the smallest at 9.2.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| TradingView | 10.0 |
| Proactive Investors UK | 10.0 |
| Investing.com | 10.0 |
| Sharecast | 9.2 |
| London South East | 9.2 |
| Moomoo | 9.2 |
| Stock Titan | 9.2 |
| Outlet | Headlines | Average tone |
|---|---|---|
| TradingView | 2 | +10.0 |
| Proactive Investors UK | 1 | +10.0 |
| Investing.com | 1 | +10.0 |
| Sharecast | 1 | +9.2 |
| London South East | 1 | +9.2 |
| Moomoo | 1 | +9.2 |
| Stock Titan | 1 | +9.2 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Most rectal patients avoided surgery and chemotherapy after treatment. |
| +10.0 | High tumour clearance rate in rectal cancer trial. |
| +10.0 | Official release confirms high complete response rate. |
| +9.2 | Promising results in two tumour types. |
| +9.2 | Favourable trial outcomes in two cancer types. |
| +9.2 | Favourable interim mid-stage rectal cancer findings. |
| +9.2 | Responders showed no relapse so far in rectal cancer trial. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Positive interim phase II results for Jemperli monotherapy. |
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.